抗肿瘤新药洛铂治疗转移性乳腺癌的研究进展  

Research progress of new anticancer drug lobaplatin in treatment of metastatic breast cancer

作　　者：孙旭[1] 隋东虎(综述)[1] 徐兵河(审校)[2] 

机构地区：[1]贵州益佰制药股份有限公司医学部,贵阳550008 [2]中国医学科学院肿瘤医院肿瘤内科

出　　处：《肿瘤研究与临床》2013年第9期646-648,共3页Cancer Research and Clinic

摘　　要：洛铂是具有自主知识产权的第三代铂类抗肿瘤药品。大量基础和临床研究表明，洛铂可有效抑制乳腺癌包括阴性乳腺癌细胞的体外增殖；含洛铂方案治疗转移性乳腺癌（MBC）的疗效与国际标准的顺铂方案相当，安全性和耐受性更好，已成为MBC治疗的新选择，有待进一步开展优化临床合理用药的研究。As the third generation platinum antitumor drug with independent intellectual property rights,a number of basic and clinical reseawh shows lobaplatin can effectively inhibit the proliferation of human breast cancer cell lines including triple-negative breast cancer in vivo. Compared with the cisplatin- based regimens, lobaplatin-based regimens have similar efficacy, and better safety profile.It becomes the new treatment option of metastatic breast cancer, and remains to be further study to optimize clinical rational drug use.

关 键 词：洛铂 转移性乳腺癌 药效学 临床研究 

分 类 号：R737.9[医药卫生—肿瘤]